

[Open Peer Review on Qeios](#)

# TGFbeta Inhibitor LY3200882

National Cancer Institute

## Source

National Cancer Institute. *TGFbeta Inhibitor LY3200882*. NCI Thesaurus. Code C132013.

An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.